Poolbeg Pharma announced on Friday that it has conditionally raised a total of £4.865m in gross proceeds through an upsized ...

The autologous immunotherapy consists of the patient’s own T cells engineered to express a chimeric antigen receptor that ...

(NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that it has entered into definitive agreements for the issuance and sale of an ...

IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has filed ...

An engineered viral protein enhanced the anticancer function of T cells in mice, suggesting a new strategy to improve ...

IMUNON’s Phase 2 OVATION 2 trial of IMNN-001 in advanced ovarian cancer showed a 13-month OS increase (46 vs. 33 months) and ...

In trials, the drug has been effective in some tumors, but researchers at the University of Turku in Finland hope to identify biomarkers to better select patients.

Pelareorep initiates a pro-inflammatory tumor microenvironment (TME) and induces innate and adaptive immune responses New ...